Peginesatide (Omontys) is a recombinant erythropoiesis-stimulating agent (ESA) approved by the US Food and Drug Administration (FDA) for the treatment of anemia in adult patients with chronic kidney disease (CKD) on dialysis. Peginesatide is a form of synthetic human erythropoietin (EPO), a hormone that stimulates the production of red blood cells. It is administered as a subcutaneous injection once every four weeks. Peginesatide is thought to be more effective than other ESAs in raising hemoglobin levels and reducing the amount of transfusions required by patients with CKD. It may also have a lower risk of cardiovascular complications associated with traditional ESAs.
Peginesatide was a medication designed to treat anemia caused by chronic kidney disease (CKD) in adult patients on dialysis. It functioned like erythropoietin, a natural hormone that stimulates red blood cell production. However, it's important to note that peginesatide is no longer available in the US market due to withdrawal by the manufacturer in 2013.
Here's a breakdown of key points about peginesatide:
What it was for:
- Treatment of anemia in adult CKD patients undergoing dialysis.
How it worked:
- Peginesatide mimicked the effects of erythropoietin, stimulating the bone marrow to produce more red blood cells.
- Unlike erythropoietin, it was a synthetic peptide attached to polyethylene glycol (PEG), which helped it last longer in the body.
Important to know:
- Peginesatide was withdrawn from the market due to concerns about hypersensitivity reactions.
- There are other erythropoiesis-stimulating agents (ESAs) available for treating anemia in CKD patients.